Upstream Bio, Inc./$UPB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Upstream Bio, Inc.

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.

Ticker

$UPB

Sector

Health
Primary listing
NASDAQ

Employees

52
Headquarters
Waltham, United States
Website
upstreambio.com

UPB Metrics

BasicAdvanced
$854M
-
-$3.02
-
-

Bulls say / Bears say

Upstream Bio's lead drug, verekitug, is progressing through multiple Phase 2 trials targeting severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD), indicating a robust pipeline with potential for significant market impact. (Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights)
The company completed an upsized initial public offering in October 2024, raising approximately $293 million, which extends its financial runway through 2027, providing ample resources to advance its clinical programs. (Upstream Bio Announces Pricing of Upsized Initial Public Offering)
Recent strategic appointments, including Daniella Beckman to the Board of Directors and Allison Ambrose as General Counsel, bring extensive industry experience that could enhance corporate governance and operational efficiency. (Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights)
Upstream Bio reported a net loss of $21.2 million for Q4 2024, an increase from $11.8 million in the same period in 2023, primarily due to rising research and development expenses, which may raise concerns about financial sustainability. (Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights)
The company's stock price has experienced significant volatility, with a 52-week range between $5.85 and $29.46, which may indicate market uncertainty regarding its future prospects. (Upstream Bio, Inc.’s Lock-Up Period Will Expire on April 9th (NASDAQ:UPB))
As a clinical-stage biotechnology company, Upstream Bio faces inherent risks associated with drug development, including potential delays or failures in clinical trials, which could adversely affect its stock performance. (Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $UPB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs